Voyage au bout de la viande, la face cachée d’une production effrénée

Arte mène l’enquête sur une filière puissante et opaque : l’industrie de la viande

De la crise de la vache folle à l’affaire de la viande de cheval vendue comme du boeuf, Arte mène un périple de 7 000 kilomètres à travers l’Europe pour comprendre que la viande dans nos assiettes cache des secrets peu ragoûtants.

Plus d’information
  • Voyage au bout de la viande, arte.tv, 31 mars 2015.
  • Voyage au bout de la viande, mrmondialisation, 8 avril 2015.
  • Viande : la face cachée d’une production effrénéearte.tv, 9 avril 2015.
  • Regardez plus de vidéos sur notre chaine YouTube.

College evidence supports full-time Stilbosol feeding

DES advert, FFA National Future Farmer, 1959

image of stillbosol feeding advert
Stilbosol patenting turned the cattle feed industry upside down in the mid fifties with its phenomenal use by the farmers.
Image Sources
Related posts
Related books
More DES DiEthylStilbestrol Resources

Breastfeeding reduces risk of breast cancer recurrence

Study finds tumor type may also influence outcomes

breastfeeding image
Breast-feeding may reduce risk of breast cancer recurrence, and death. Image by Chris Alban Hansen.

Women diagnosed with breast cancer who previously breastfed their babies had a 30 percent overall decreased risk of the disease recurring, according to a new study.

Breast feeding for six months or more was associated with even greater protection from tumour recurrence. In addition to the reduced risk of recurrence, the researchers found a 28 percent reduced risk of dying from the disease among women who breast-fed.

Sources and more information
  • History of breastfeeding associated with reduced risk of breast cancer recurrence, eurekalert, 28-APR-2015.
  • Breastfeeding, PAM50 Tumor Subtype, and Breast Cancer Prognosis and Survival, JNCI J Natl Cancer Inst (2015) 107 (7): djv087 doi: 10.1093/jnci/djv087.

Thimerosal in Vaccines and Autism

It’s not the vaccines that appear to be one cause of neurological disorders but Thimerosal

Growing numbers of Americans are refusing to vaccinate their children because they think vaccines are causing autism. But it’s not the vaccines that appear to be one cause of neurological disorders, it’s something else. Now, a senior CDC vaccine safety scientist has invoked the protection of the Federal Whistleblower Statute, and is claiming that the CDC knew that thimerosal was unsafe, but pressured him to publish studies claiming otherwise.

More information

U.S. Senator Scott Brown and DES activists, 2010

Watch @DES_Journal diaporama and DES Info album on Flickr.

Senator-Brown-and-DES-activists image
WONDER DRUG screenwriter Caitlin McCarthy; US Senator Scott Brown; and Andrea Goldstein (former President of DES Action USA) at the Senator’s 2010 Christmas Party, taken by event photographer Katie Kaizer at the Senator’s Christmas Party at the Boston Park Plaza Hotel.

On February 22, 2011, US Senator John Kerry and US Senator Scott Brown received a 3-page response from the FDA, per their joint letter about a DES apology. The FDA’s letter did not contain an official apology from the federal government for the DES drug disaster. However, it acknowledged the devastating health consequences of DES, explained FDA initiatives to prevent future drug disasters, and talked about DES as a “tragedy“.

The FDA closed the letter by writing, “We hope that our new tools for identifying, monitoring and mitigating drug risks will prevent other tragedies like those brought out by the widespread use of DES. We are committed to providing the public with timely and accurate drug safety information and we recognize the critical responsibility that the FDA has to protect the safety of the public’s health“.

More information

  • Image source: DES (Diethylstilbestrol) Info DES News on Facebook, 26 July 2012.
  • FDA Response on DES Letter, WONDER DRUG Facebook album, 22 February 2011.
  • The DES (Diethylstilbestrol) Drug Disaster, 40 Years Later: The Tragedy Is Far From Over, desinfo411, April 22, 2011.
  • FDA Acknowledges, But Doesn’t Apologize For, DES Drug Disaster, desinfo411, April 19, 2011.
More DES DiEthylStilbestrol Resources

Recours collectif santé: les pistes pour améliorer le projet de loi

Projet de loi de modernisation de notre système de santé

Le contenu de ce post est publié par weclaim, “plateforme de litiges de masse en ligne qui permet à des victimes d’être indemnisées grâce à une procédure simple et financée, et à une technologie IT de pointe”.

image de l'assemblée-nationale
L’Assemblée nationale vient d’adopter en première lecture le projet de loi santé. Ce texte prévoit la possibilité de lancer des actions de groupe dans le domaine médical. Image via Dennis Jarvis.

Après l’entrée en vigueur le 1er octobre 2014 de la loi autorisant l’action de groupe pour les litiges en matière de consommation et de concurrence, dite “loi Hamon”, le projet de loi relatif à la santé prévoit l’introduction d’une action de groupe en matière de dommage corporel.

En l’état actuel, la procédure d’action de groupe prévue au projet de loi santé ne permet pas une indemnisation rapide des victimes. La procédure d’établissement d’une faute du professionnel, couplée à l’épuisement des voies de recours, prendra une dizaine d’années et aura deux effets négatifs :

  • le découragement des victimes, empêchant la constitution d’un groupe,
  • et/ou la perte ou la destruction des documents de preuve.

Seul l’opt-out permettrait une indemnisation efficace : les victimes n’ont pas besoin de s’inscrire à l’action de groupe, et le professionnel est incité à négocier. Il y a peu de chance que le projet de loi soit modifié en ce sens. Ainsi, l’offre de Weclaim est particulièrement attrayante, en ce qu’elle permet:

  • la constitution effective et rapide d’un groupe par l’enregistrement immédiat des plaintes,
  • et la sauvegarde en ligne de toute preuve.

Egalement, l’introduction de la médiation est louable, mais son efficacité s’annonce douteuse : les victimes restent invisibles tout au long de la procédure, jusqu’au jugement de la faute, ce qui n’incitera pas ou peu les professionnels à négocier. Regrouper et rendre visibles de très nombreuses victimes est un des leviers les plus puissants pour obtenir un accord transactionnel. C’est précisément ce que permet Weclaim, en favorisant la constitution d’un groupe de victimes très rapidement.

S’agissant de l’introduction des actions de groupe, le législateur fait à nouveau l’erreur du monopole, qui comporte au moins deux défauts :

  • la multiplication des actions, engendrant un éclatement du groupe et des décisions contradictoires,
  • et l’insuffisance des ressources humaines et financières des associations pour conduire ces procédures.

La défense des intérêts en justice ne s’improvise pas. Weclaim peut pallier à ces défauts en fédérant les initiatives des associations et en assurant le financement de leurs litiges.

L’absence de juridiction unique compétente constitue un autre sujet de préoccupation. Alors que nos voisins européens font justement le choix de la spécialisation des tribunaux pour ce type de litige, on comprend mal l’éparpillement du contentieux introduit par le législateur, qui aboutira à des solutions jurisprudentielles hétéroclites par les 339 juridictions théoriquement compétentes (sans compter les juridictions d’appel).

Plus grave, le choix de circonscrire l’indemnisation au seul dommage corporel est incompréhensible. Quid de la réparation des dommages moraux ? Certes, il s’agit d’un dommage spécifique à chaque victime que le législateur a exclu de la loi pour gagner en efficacité. Mais est-ce à dire que la victime pourra être indemnisée pour son dommage corporel, au travers d’une action de groupe, et qu’elle devra intenter une procédure individuelle pour l’évaluation et la réparation du dommage moral subi ?

Plus d’information
  • Projet de loi de modernisation de notre système de santé (AFSX1418355L), legifrance, jeudi 16 avril 2015.
  • Les actions de groupe en santé pourraient être rétroactives, lecomparateurassurance, 14 avril 2015.
  • Ce que la loi de santé va changer pour les Français, lesechos, 14 avril 2015.
  • Loi santé : “L’action de groupe ne permettra pas une indemnisation rapide des victimes”, lepoint, 10 avril 2015.

Thimerosal in Vaccines and Autism

It’s not the vaccines that appear to be one cause of neurological disorders but Thimerosal

Growing numbers of Americans are refusing to vaccinate their children because they think vaccines are causing autism. But it’s not the vaccines that appear to be one cause of neurological disorders, it’s something else. Now, a senior CDC vaccine safety scientist has invoked the protection of the Federal Whistleblower Statute, and is claiming that the CDC knew that thimerosal was unsafe, but pressured him to publish studies claiming otherwise.

More information

Epigenetics: Current Research and Emerging Trends

Epigenetics can have a significant impact on human health and disease susceptibility

EpigeneticsOver the past few years significant progress has occurred in this rapidly advancing field and much key research has been published.

The editor of Epigenetics: Current Research and Emerging Trends book has gathered together pioneers in the field of epigenetics to produce a volume of thought-provoking discussions on classic aspects of epigenetics and on the newer, emerging areas. The 17 chapters include topics on the impact of metabolism on the epigenome, how our actions may impact the health of our offspring several generations removed, and how exposure to environmental toxicants can have long-lasting effects on our epigenome with devastating consequences.

This up-to-date volume is a major resource essential for those working in the field and is recommended reading for anyone new to this fascinating and fast-moving area of research. Sources: horizonpress and PDF.

Table of contents
  1. The Multifaceted Roles of YY1 in the Establishment of the Cellular Epigenetic Landscape
  2. SETting up the Epigenome Through the Histone Methyltransferase SETDB1
  3. Sirtuin Deacetylases in Fungi: Connecting Metabolism to Lifecycle Progression, Stress Response, and Genome Stability
  4. Development-linked Differences in Cytosine 5-Hydroxymethylation in Mammalian DNA: Relationship to 5-Methylcytosine and Function
  5. The Identification of Mammalian Proteins Involved in Epigenetics
  6. Chromatin-mediated Response to Stimuli
  7. The Epigenetics of Centromere Function
  8. Dosage Compensation in Frogs and Toads
  9. Ingenious Genes: The Diverse Roles of Long Noncoding RNA in Regulatory Processes
  10. Epigenetic Mechanisms in Rett Syndrome
  11. The Long and Short of Facioscapulohumeral Muscular Dystrophy
  12. The Epigenetics of Nuclear Reprogramming to Pluripotency
  13. Emerging Role of the Guanine-Quadruplex DNA Secondary Structure in Epigenetics
  14. Clinical Epigenetics in Cancer: Applications in Diagnosis, Prognosis and Therapy
  15. Environment and the Epigenetic Transgenerational Inheritance of Disease
  16. Metabolic Inputs into Epigenetics
  17. Environmental Exposures: Impact on the Epigenome
On Flickr®

Prenatal Diethylstilbestrol Exposure and Risk of Uterine Leiomyomata

First-trimester DES exposure may be associated with an increased risk of uterine leiomyomata

image of Uterine Leiomyomata
These 2013 results suggest that first-trimester DES exposure may be associated with an increased risk of uterine leiomyomata. The association was highest for women exposed to DES in the first trimester, which corresponds to early stages of fetal mullerian development. Image by Nephron via Wikimedia Commons.

2013 Study Abstract

Previous studies evaluating the association of prenatal exposure to diethylstilbestrol (DES), a potent endocrine disruptor, with incidence of uterine leiomyomata (UL) have had conflicting results. We evaluated the association between prenatal DES exposure and incident UL in women in the Nurses’ Health Study II from 1989 to 2009. Women were aged 25–42 years at enrollment and had a prenatal exposure window corresponding to DES use. The analytical sample was larger than previous studies and included 102,164 premenopausal women with intact uteri, no prior history of UL or cancer, and prenatal DES exposure. Multivariable-adjusted Cox proportional hazard models were used to estimate the relationship between DES exposure and UL risk. During 1,273,342 person-years of follow-up, there were 11,831 incident cases of UL. Women with prenatal exposure to DES had a higher incidence of UL compared with unexposed women, with an adjusted hazard ratio of 1.12 (95% confidence interval: 0.98, 1.27). Risk was strongest for women exposed to DES in the first trimester, when exposure corresponds to early stages of fetal Müllerian development (adjusted hazard ratio = 1.21, 95% confidence interval: 1.02, 1.43). These results suggest that first-trimester DES exposure may be associated with an increased risk of UL, but they must be interpreted with concern for detection and recall biases.

2013 Study Conclusions

We found a small positive association between DES exposure and risk of UL. Among women reporting trimester of DES initiation, the association was strongest when DES was initiated in the first trimester. These results should be interpreted with caution because of the possibility of recall bias in both participants and their mothers, as well as detection bias due to increased gynecological surveillance in exposed women. Because DES-exposed women are aging out of leiomyomata research, the possibility for future study of this association is limited. However, studies of DES exposure and outcomes of concern may provide a framework for other similarly acting estrogenic endocrine disruptors, such as Bisphenol A and dioxin.

Sources and Full Study
  • Prenatal Diethylstilbestrol Exposure and Risk of Uterine Leiomyomata in the Nurses’ Health Study II, Oxford Journals, American Journal of Epidemiology, doi: 10.1093/aje/kwt250, 179 (2): 186-191, October 18, 2013.
More DES DiEthylStilbestrol Resources

Les infiltrés: au coeur des laboratoires pharmaceutiques

2013: Sophie Bonnet enquête sur les laboratoires pharmaceutiques

Les laboratoires pharmaceutiques sont habituellement fermés aux médias. L’équipe de journalistes du magazine de France 2 est parvenue à pénétrer cette industrie, souvent décrite comme l’un des plus puissants lobbys au monde. Documentaire de Sophie Bonnet diffusé le 22 février 2013 sur France 2.

Plus d’information